Nuvectis Pharma (NVCT) Competitors $5.10 +0.20 (+4.08%) (As of 11/22/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends NVCT vs. VALN, BTMD, KMDA, ACIU, JSPR, DSGN, KOD, CYRX, QTTB, and SAGEShould you be buying Nuvectis Pharma stock or one of its competitors? The main competitors of Nuvectis Pharma include Valneva (VALN), biote (BTMD), Kamada (KMDA), AC Immune (ACIU), Jasper Therapeutics (JSPR), Design Therapeutics (DSGN), Kodiak Sciences (KOD), Cryoport (CYRX), Q32 Bio (QTTB), and Sage Therapeutics (SAGE). These companies are all part of the "pharmaceutical products" industry. Nuvectis Pharma vs. Valneva biote Kamada AC Immune Jasper Therapeutics Design Therapeutics Kodiak Sciences Cryoport Q32 Bio Sage Therapeutics Nuvectis Pharma (NASDAQ:NVCT) and Valneva (NASDAQ:VALN) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, analyst recommendations, dividends, community ranking, earnings, profitability, valuation, institutional ownership and risk. Do institutionals and insiders hold more shares of NVCT or VALN? 96.8% of Nuvectis Pharma shares are held by institutional investors. Comparatively, 11.4% of Valneva shares are held by institutional investors. 35.8% of Nuvectis Pharma shares are held by insiders. Comparatively, 14.9% of Valneva shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Is NVCT or VALN more profitable? Nuvectis Pharma has a net margin of 0.00% compared to Valneva's net margin of -4.35%. Valneva's return on equity of -3.93% beat Nuvectis Pharma's return on equity.Company Net Margins Return on Equity Return on Assets Nuvectis PharmaN/A -155.80% -104.02% Valneva -4.35%-3.93%-1.42% Which has better earnings & valuation, NVCT or VALN? Nuvectis Pharma has higher earnings, but lower revenue than Valneva. Valneva is trading at a lower price-to-earnings ratio than Nuvectis Pharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNuvectis PharmaN/AN/A-$22.26M-$1.16-4.40Valneva$165.52M2.17-$109.78M-$0.13-34.08 Does the media prefer NVCT or VALN? In the previous week, Nuvectis Pharma had 3 more articles in the media than Valneva. MarketBeat recorded 5 mentions for Nuvectis Pharma and 2 mentions for Valneva. Nuvectis Pharma's average media sentiment score of 1.03 beat Valneva's score of 0.06 indicating that Nuvectis Pharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nuvectis Pharma 2 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Valneva 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts prefer NVCT or VALN? Nuvectis Pharma presently has a consensus price target of $21.00, suggesting a potential upside of 311.76%. Valneva has a consensus price target of $18.50, suggesting a potential upside of 317.61%. Given Valneva's higher possible upside, analysts clearly believe Valneva is more favorable than Nuvectis Pharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nuvectis Pharma 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Valneva 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the MarketBeat Community prefer NVCT or VALN? Valneva received 23 more outperform votes than Nuvectis Pharma when rated by MarketBeat users. However, 90.00% of users gave Nuvectis Pharma an outperform vote while only 60.38% of users gave Valneva an outperform vote. CompanyUnderperformOutperformNuvectis PharmaOutperform Votes990.00% Underperform Votes110.00%ValnevaOutperform Votes3260.38% Underperform Votes2139.62% Which has more volatility & risk, NVCT or VALN? Nuvectis Pharma has a beta of 0.41, meaning that its stock price is 59% less volatile than the S&P 500. Comparatively, Valneva has a beta of 2.17, meaning that its stock price is 117% more volatile than the S&P 500. SummaryNuvectis Pharma and Valneva tied by winning 8 of the 16 factors compared between the two stocks. Ad DTILet’s be bluntLet me be blunt with you for just a second… You may think you know when and why stocks move, but you’re wrong… Most traders have no idea about the biggest secret Wall Street keeps — even though it’s hiding in plain sight. But once you’ve cracked this code… It could be the breakthrough you need to start targeting $100-$150 a day in the stock market (starting with just $1,000)! Check out the $100 Challenge now Get Nuvectis Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for NVCT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NVCT vs. The Competition Export to ExcelMetricNuvectis PharmaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$98.53M$6.99B$5.38B$8.84BDividend YieldN/A8.15%5.13%4.09%P/E Ratio-4.4011.10105.1417.83Price / SalesN/A362.031,233.15158.41Price / CashN/A52.5940.4136.29Price / Book8.9510.377.096.50Net Income-$22.26M$153.60M$119.65M$226.22M7 Day Performance3.03%4.60%2.25%4.03%1 Month Performance-40.00%-6.29%-2.33%4.92%1 Year Performance-37.65%33.41%33.98%29.30% Nuvectis Pharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NVCTNuvectis Pharma3.5441 of 5 stars$5.10+4.1%$21.00+311.8%-37.7%$98.53MN/A-4.408VALNValneva2.3222 of 5 stars$4.29-2.9%$18.50+331.2%-63.3%$348.56M$165.52M-34.00700BTMDbiote3.0194 of 5 stars$6.24+1.6%$8.39+34.4%+15.9%$338.33M$185.36M23.62194KMDAKamada3.8019 of 5 stars$5.83-0.3%$14.50+148.7%+23.6%$335.11M$142.52M20.89360ACIUAC Immune2.3064 of 5 stars$3.34+1.5%$12.00+259.3%+11.9%$330.46M$40.97M-7.15140JSPRJasper Therapeutics2.6549 of 5 stars$21.98+0.6%$74.86+240.6%+254.2%$329.70MN/A-4.6120DSGNDesign Therapeutics0.6632 of 5 stars$5.68+2.0%$7.00+23.2%+154.3%$321.60MN/A-6.5440KODKodiak Sciences2.979 of 5 stars$6.10+3.4%$3.50-42.6%+157.9%$320.98MN/A-1.6290CYRXCryoport2.8687 of 5 stars$6.49-0.5%$12.50+92.6%-53.2%$320.81M$226.11M-1.951,170Insider TradeQTTBQ32 Bio1.6143 of 5 stars$26.21-3.1%$72.33+176.0%N/A$319.24M$1.16M-1.9039SAGESage Therapeutics4.3758 of 5 stars$5.04+3.9%$12.83+154.6%-73.4%$308.31M$106.40M-0.87690Analyst Forecast Related Companies and Tools Related Companies VALN Alternatives BTMD Alternatives KMDA Alternatives ACIU Alternatives JSPR Alternatives DSGN Alternatives KOD Alternatives CYRX Alternatives QTTB Alternatives SAGE Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:NVCT) was last updated on 11/23/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nuvectis Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Nuvectis Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
